(RZB) Reinsurance of America - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7593518027

RZB: Life, Health, Reinsurance, Insurance, Financial, Products

Reinsurance Group of America, or RGA, is a global leader in the reinsurance sector, operating at the intersection of risk management and capital efficiency. With a presence spanning the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific, RGA is a critical player in the global insurance ecosystem.

The company specializes in a broad spectrum of life and health reinsurance products, covering term life, credit life, universal life, whole life, group life and health, joint and last survivor insurance, critical illness, disability, and longevity products. These offerings are designed to mitigate mortality, morbidity, lapse, and investment-related risks, providing a comprehensive risk management solution for insurers.

RGA also excels in asset-intensive and financial reinsurance, along with other capital-motivated solutions. These products are tailored to address investment-related risks, making RGA a go-to partner for insurers seeking to optimize their capital structures and manage financial volatility.

Beyond traditional reinsurance, RGA has developed a robust technology platform and provides consulting and outsourcing services. These offerings enable insurers to enhance operational efficiency, streamline processes, and leverage advanced data analytics, positioning RGA as a forward-thinking leader in the industry.

From a financial perspective, RGA boasts a market capitalization of approximately $8.7 billion, with a price-to-earnings ratio of 4.06, indicating a valuation that reflects its stable earnings and growth prospects. The companys price-to-sales ratio of 0.40 underscores its attractive valuation relative to its revenue generation.

Investors and fund managers should recognize RGAs strategic position in a rising interest rate environment, which could enhance the companys investment income and overall profitability. Additionally, RGAs diversified geographic presence and broad product portfolio provide resilience against regional market fluctuations, making it a compelling consideration for those seeking exposure to the reinsurance sector.

Additional Sources for RZB Stock

RZB Stock Overview

Market Cap in USD 8,654m
GiC Sub-Industry Reinsurance
IPO / Inception 2016-06-13

RZB Stock Ratings

Growth 5y 57.7%
Fundamental 11.2%
Dividend 50.3%
Rel. Strength Industry -11.3
Analysts -
Fair Price Momentum 24.81 USD
Fair Price DCF 3449.06 USD

RZB Dividends

Dividend Yield 12m 4.41%
Yield on Cost 5y 6.05%
Annual Growth 5y 0.00%
Payout Consistency 96.7%

RZB Growth Ratios

Growth Correlation 3m 71.9%
Growth Correlation 12m 88%
Growth Correlation 5y 64.8%
CAGR 5y 6.73%
CAGR/Max DD 5y 0.19
Sharpe Ratio 12m 1.00
Alpha 0.61
Beta 0.10
Volatility 5.50%
Current Volume 18.1k
Average Volume 20d 27.7k
What is the price of RZB stocks?
As of March 12, 2025, the stock is trading at USD 24.64 with a total of 18,073 shares traded.
Over the past week, the price has changed by -0.12%, over one month by +0.70%, over three months by +0.76% and over the past year by +5.42%.
Is Reinsurance of America a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Reinsurance of America is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 11.19 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RZB as of March 2025 is 24.81. This means that RZB is currently overvalued and has a potential downside of 0.69%.
Is RZB a buy, sell or hold?
Reinsurance of America has no consensus analysts rating.
What are the forecast for RZB stock price target?
According to ValueRays Forecast Model, RZB Reinsurance of America will be worth about 26.8 in March 2026. The stock is currently trading at 24.64. This means that the stock has a potential upside of +8.77%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 26.8 8.8%